HB 1772 — relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.
Last action — Signed by Governor Ayotte 07/15/2026; Chapter 333; eff. 09/13/2026
-
✓Introduced
-
✓In Committee
-
✓Passed House
-
✓Passed Senate
-
✓To Executive
-
6Enacted
This bill has been enacted into law. Introduced December 17, 2025. Enacted.
Signed by Governor Kelly Ayotte (Republican) on July 20, 2026.
Odds of enactment
High chanceBased on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
Enacted
Current position in the legislative process.
-
8 sponsors
1 primary, 7 co-sponsors signed on.
-
Bipartisan support
Sponsored across 2 parties (7 R · 1 D) — cross-party backing.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
In plain language
The bill allows ibogaine to be prescribed for investigational use and adopts a physician associate licensure compact.
This legislation permits the prescribing of ibogaine solely for investigational uses and establishes a licensure compact for physician associates. This could enhance access to care and treatment options for specific health conditions.
What this means for you
- Workers: This could lead to more job opportunities for physician associates due to easier licensing across states.
- Healthcare: This means healthcare providers can explore new treatment options with ibogaine within investigational protocols.
Summary
(Second New Title) relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.
Bill Text
What changed in the latest version
693 added · 752 removedPlain-language change summary
The recent changes to Bill HB 1772 allow licensed healthcare providers to prescribe ibogaine strictly for research purposes under FDA-approved protocols. This is important because ibogaine has potential therapeutic benefits for substance use disorders, and making it available for investigational use could help explore its effectiveness. Additionally, the bill adopts the physician associate licensure compact, which enhances the ability of physician associates to provide services across state lines. This change aims to improve access to healthcare and streamline the licensure process, ultimately benefiting patients seeking medical assistance.
CHAPTER 333 HB 1772-FN-A - VERSIONFINAL ADOPTEDVERSION BY BOTH BODIES 11Mar2026...
Permits licensed health care providers to administer ibogaine under the framework of an FDA-approvedFDA- approved research protocol.
CHAPTER 333 HB 1772-FN-A - VERSIONFINAL ADOPTEDVERSION BY BOTH BODIES 11Mar2026...
1333:1 New Subdivision;
2333:2 New Section;
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 2 - In this compact:
“Adverse action” means any administrative, civil, equitable, or criminal action permitted by a state’s laws which is imposed by a licensing board or other authority against a PA license or license CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 2 - application or compact privilege such as license denial, censure, revocation, suspension, probation, monitoring of the licensee, or restriction on the licensee’s practice.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 3 - O.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 3 - S.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 4 - 1.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 4 - 8.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 5 - D.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 5 - A.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 6 - C.
All disciplinary orders by the participating state which issued the qualifying license CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 6 - that impose adverse action against a PA’s license shall include a statement that the PA’s compact privilege is deactivated in all participating states during the pendency of the order.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 7 - 3.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 7 - 8.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 8 - 13.
Notwithstanding subsection D.1 of this section, the commission may convene a public meeting by providing at least 24 hours prior notice on the commission’s website, and any other means as provided CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 8 - in the commission’s rules, for any of the reasons it may dispense with notice of proposed rulemaking under section 9.L.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 9 - d.
The commission may levy on and collect an annual assessment from each participating state and may impose compact privilege fees on licensees of participating states to whom a compact privilege is granted to cover the cost of the operations and activities of the commission and its staff, which must be in a total amount sufficient to cover its annual budget as approved by the commission each year for which CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 9 - revenue is not provided by other sources.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 10 - b.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION ADOPTED BY BOTH BODIES - Page 1110 - e.
The executive committee may convene in a closed, non-public meeting for the same reasons that the commission may convene in a non-public meeting as set forth in section 7.D7.D.3 3 and shall announce the closed meeting as the commission is required to under section 7.D.4 and keep minutes of the closed meeting as the commission is required to under section 7.D.5.
The commission shall indemnify and hold harmless any member, officer, executive director, employee, and representative of the commission for the amount of any settlement or HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 12 - judgment obtained against that person arising out of any actual or alleged act, error, or omission that occurred within the scope of commission employment, duties, or responsibilities, or that such person had a reasonable basis for believing occurred within the scope of commission employment, duties, or responsibilities, provided that the actual or alleged act, error, or omission did not result from the intentional or willful or wanton misconduct of that person.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 11 - 4.
and HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 13 - 6.
The commission shall promptly notify all participating states of any adverse action taken against a licensee or an individual applying for a license that has been reported to it.itThis adverse action information shall be available to any other participating state.
This adverse action information shall be available to any other participating state.
Participating states contributing information to the data system may, in accordance with state or federal law, designate information that may not be shared with the public without the express permission CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 12 - of the contributing state.
The commission shall exercise its rulemaking powers pursuant to the criteria set forth in this section and the rules adopted thereunder.thereunderCommission rules shall become binding as of the date specified by the commission for each rule.
Commission rules shall become binding as of the date specified by the commission for each rule.
If a majority of the legislatures of the participating states reject a commission rule, by enactment of a statute or resolution in the same manner used to adopt this compact within 4 years of HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 14 - the date of adoption of the rule, then such rule shall have no further force and effect in any participating state or to any state applying to participate in the compact.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 13 - 3.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 15 - K.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 14 - 1.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 16 - 2.
If a state in default fails to cure the default, the defaulting state may be terminated from this compact upon an affirmative vote of a majority of the delegates of the participating states, and all rights, privileges and benefits conferred by this compact upon such state may be terminated on the effective date CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 15 - of termination.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 17 - 7.
Upon request by a participating state, the commission shall attempt to resolve disputes related to this compact that arise among participating states and between participating and non-non-participating participating states.
Show all 62 changed lines (22 more)
In the event judicial CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 16 - enforcement is necessary, the prevailing party shall be awarded all costs of such litigation, including reasonable attorney’s fees.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 18 - A.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 17 - 1.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 19 - 3.
CHAPTER 333 HB 1772-FN-A - FINAL VERSION - Page 18 - A.
HB 1772-FN-A - VERSION ADOPTED BY BOTH BODIES - Page 20 - C.
3333:3 Effective Date.
LBAApproved: 26-2533 05/21/2026 HB 1772-FN-A- FISCAL NOTE AS AMENDED BY THE SENATE (AMENDMENTS #2026-1623s and #2026-1916s) AN ACT relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.
FISCALJuly IMPACT:15, 2026 Effective Date:
ThisSeptember bill13, does2026 not provide funding, nor does it authorize new positions.
Estimated State Impact FY 2026 FY 2027 FY 2028 FY 2029 Revenue $0 Indeterminable (section 2) Revenue Fund(s) Office of Professional Licensure and Certification Fund Indeterminable increase of Expenditures* $0 $10,000 or more Indeterminable increase (section 2) (section 2) Funding Source(s) Office of Professional Licensure and Certification Fund Appropriations* $0 $0 $0 $0 Funding Source(s) None *Expenditure = Cost of bill *Appropriation = Authorized funding to cover cost of bill METHODOLOGY:
Section 1 of this bill permits licensed health care providers to administer ibogaine under the framework of a federally-approved research protocol.
This section is expected to have no fiscal impact.
Section 2 adopts the Physician Associate Licensure Compact by allowing a Physician Associate (PA) with an unrestricted license in one participating state to obtain a compact privilege to practice in another participating state.
The Office of Professional Licensure and Certification (OPLC) states that it would need to adopt and implement the PA Licensure Compact and create a new compact license type within its licensing system.
The estimated one time cost to upgrade the software to support this new license type is $10,000.
OPLC also notes that enforcement activity may increase if complaints arise involving PAs practicing in New Hampshire under compact privileges, but the associated cost cannot be estimated because the number of potential complaints is unknown.
Because the compact allows PAs to practice in New Hampshire through a compact privilege rather than holding a standard New Hampshire license, OPLC anticipates a reduction in PA license revenue.
Of the 1,636 current PA licensees, 488 have a home address outside New Hampshire, and if these individuals rely on compact privileges instead of maintaining a NH license, OPLC estimates a potential revenue loss of approximately $93,000.
The OPLC may see some new revenue from PAs who newly designate New Hampshire as their home state for compact purposes, but because the number of such licensees cannot be predicted, any potential increase is indeterminable.
AGENCIES CONTACTED:
Office of Professional Licensure and Certification
Show all 62 changed rows (22 more)
View plain text versions (5)
- Chaptered CHAPTERED FINAL VERSION Current pdf
- Version adopted by both bodies View text pdf
- Amended As Amended by the House pdf
- Amended As Amended by the Senate pdf
- Introduced View text pdf
Action History
-
Signed by Governor Ayotte 07/15/2026; Chapter 333; eff. 09/13/2026
-
Enrolled Adopted, VV, (In recess 06/04/2026); SJ 15
-
Enrolled (in recess of) 06/04/2026 HJ 15
-
Enrolled Bill Amendment # 2026-2184e: AA VV (in recess of) 06/04/2026 HJ 15
-
Enrolled Bill Amendment # 2026-2184e Adopted, VV, (In recess of 06/04/2026); SJ 14
-
Conference Committee Report 2026-2090c: Adopted, VV 06/04/2026 HJ 15
-
Conference Committee Report # 2026-2090c, Adopted, VV; 06/04/2026; SJ 14
-
Conference Committee Report Filed, # 2026-2090c; 06/04/2026
-
Conference Committee Meeting: 05/27/2026 01:45 pm GP 231
-
President Appoints: Senators Rochefort, Pearl, Prentiss; (In Recess 05/14/2026); SJ 13
-
Sen. Rochefort Accedes to House Request for Committee of Conference, MA, VV; (In recess 05/14/2026); SJ 13
-
Speaker Appoints: Reps. W. MacDonald, Drew, Markell, Milz 05/14/2026 HJ 13 P. 152
-
House Non-Concurs with Senate Amendment 2026-1916s and 2026-1623s and Requests CofC (Rep. W. MacDonald): MA VV 05/14/2026 HJ 13 P. 152
-
Ought to Pass with Amendments #2026-1623s and #2026-1916s, MA, VV; OT3rdg; 05/14/2026; SJ 12
-
Sen. Rochefort Floor Amendment # 2026-1916s, AA, VV; 05/14/2026; SJ 12
-
Committee Amendment # 2026-1623s, AA, VV; 05/14/2026; SJ 12
-
Committee Report: Ought to Pass with Amendment # 2026-1623s, 05/14/2026, Vote 4-0; SC 18
-
Special Order to 05/14/2026, Without Objection, MA; 05/07/2026 SJ 11
-
Committee Report: Ought to Pass with Amendment # 2026-1623s, 05/07/2026, Vote 4-0; SC 17
-
Hearing: 03/25/2026, Room 100, SH, 10:00 am; SC 12
-
Introduced 03/12/2026 and Referred to Health and Human Services; SJ 7
-
Amendment # 2026-0365h: AA VV 03/11/2026 HJ 7 P. 206
-
Ought to Pass with Amendment 2026-0365h: MA DV 176-156 03/11/2026 HJ 7 P. 207
-
Minority Committee Report: Refer for Interim Study
-
Majority Committee Report: Ought to Pass with Amendment # 2026-0365h 03/04/2026 (Vote 10-8; RC) HC 10 P. 53
-
Executive Session: 03/04/2026 09:00 am GP 158
-
Public Hearing: 02/24/2026 02:00 pm GP 158
-
==CANCELLED== Public Hearing: 02/23/2026 02:00 pm GP 158
-
Introduced 01/07/2026 and referred to Health, Human Services and Elderly Affairs HJ 1 P. 35
Sponsors
- Tim McGough · Cosponsor
- Howard Pearl · Cosponsor
- Jess Edwards · Cosponsor
- Michael Moffett · Primary
- Lily Foss · Cosponsor
- Keith Ammon · Cosponsor
- Lisa Freeman · Cosponsor
- Terry Roy · Cosponsor
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 7 co-sponsors · 407 not signed on
Sponsors (1)
- Michael Moffett Republican
Co-sponsors (7)
- Tim McGough Republican
- Howard Pearl Republican
- Jess Edwards Republican
- Lily Foss Democrat
- Keith Ammon Republican
- Lisa Freeman Republican
- Terry Roy Republican
Not signed on (407)
407 members have not signed on to this bill.
Show all 407 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HB 1772 do?
- (Second New Title) relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.
- Who sponsors HB 1772?
- HB 1772 is sponsored by Tim McGough (Republican), Howard Pearl (Republican), Jess Edwards (Republican), Michael Moffett (Republican), Lily Foss (Democrat), Keith Ammon (Republican), Lisa Freeman (Republican), and Terry Roy (Republican).
- What is the current status of HB 1772?
- This bill has been enacted into law. Introduced December 17, 2025. Enacted.
- Where can I track HB 1772?
- Track HB 1772 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HB 1772
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HB 1772
Last checked for changes about 1 month ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →